Showing 1891-1900 of 5643 results for "".
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&
- Notal Vision Monitoring Center Reports AI Analysis of 10 Million ForeseeHome AMD Home Monitoring Testshttps://modernod.com/news/notal-vision-monitoring-center-reports-ai-analysis-of-10-million-foreseehome-amd-home-monitoring-tests/2480482/The Notal Vision Monitoring Center celebrates the artificial intelligence (AI) based analysis of the ten millionth test performed by over 20,000 patients with the FDA-cleared ForeseeHome devic
- IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injuryhttps://modernod.com/news/iacta-pharmaceuticals-receives-us-department-of-defense-funding-of-1-million-to-conduct-preclinical-studies-of-ic-800-to-treat-pain-relief-for-eye-injury/2480382/IACTA Pharmaceuticals announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain utilizing
- Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trialhttps://modernod.com/news/outlook-therapeutics-reports-new-positive-12-month-safety-data-from-pivotal-phase-3-norse-two-trial/2480308/Outlook Therapeutics announced new 12-month safety data from the pivotal phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010/Lytenava (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). In August 2021, Outlook Ther
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op
- Novartis Acquires Arctos Medical, Expanding Optogenetics Portfoliohttps://modernod.com/news/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-to-bring-gene-therapies-to-patients-with-severe-vision-loss/2480291/Novartis announced that it has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Financial terms of the deal were not disclosed. “Optogenetics is emergi
- Outlook Therapeutics Presents Positive NORSE THREE Safety Data for Lytenava (bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-presents-positive-norse-three-safety-data-for-lytenava-bevacizumab-vikg-at-euretina/2479575/Outlook Therapeutics announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010/Lytenava (bevacizumab-vikg) at the EURETINA Virtual 2021 conference on September 12, 2021. The previously announced topline results from the open-label safety study demonstrated that
- Retina Consultants of America Expands Into North Carolinahttps://modernod.com/news/retina-consultants-of-america-expands-into-north-carolina/2479446/Physician management services organization Retina Consultants of America (RCA) had added North Carolina Retina Associates (NC Retina Associates) to its national consortium. Terms of the deal were not disclosed. The addition of NC Retina Associates marks RCA’s first entry into the No
- Notal Vision Announces Publication First Prospective Longitudinal Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-first-prospective-longitudinal-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479365/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated Home OCT for wet age-related macular degeneration (AMD) patients have been published in
- Notal Vision Announces Publication of First Pilot Study of Daily Self-Imaging With Patient-Operated Home OCT in Wet AMD Patientshttps://modernod.com/news/notal-vision-announces-publication-of-first-pilot-study-of-daily-self-imaging-with-patient-operated-home-oct-in-wet-amd-patients/2479356/Notal Vision announced that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated home OCT for wet age-related macular degeneration